Guardant Health, Inc.·4

Jun 22, 5:50 PM ET

Azar Alex M II 4

Research Summary

AI-generated summary

Updated

Guardant Health (GH) Director Alex Azar Receives 2,711 RSU Award

What Happened

  • Azar Alex M II (Director) received an award of 2,711 restricted stock units (RSUs) on June 17, 2026. The award is reported as a derivative grant (code A) with no purchase price ($0).
  • This was an equity award (compensation), not a purchase or sale of shares. No cash changed hands at grant.

Key Details

  • Transaction date: June 17, 2026. Report filed: June 22, 2026.
  • Price/consideration: $0 (typical for RSU grants); transaction type: Award/Grant (A), derivative security.
  • Shares owned after transaction: Not specified in the filing.
  • Footnotes: F1 — the RSUs vest in full on the one-year anniversary of the grant date, June 17, 2026, or at the company's next annual meeting of stockholders, whichever is earlier. F2 — not applicable for Restricted Stock Units.
  • Timeliness: Filing was submitted on June 22 for a June 17 transaction — this appears to be after the usual Form 4 deadline (insiders generally must file within 2 business days), so it may be late.

Context

  • RSUs are a promise to deliver shares (or equivalent value) upon vesting; they do not represent immediate share ownership or sale. Such awards are common director compensation and do not by themselves indicate buying or selling intent.
  • Because this is a grant/award rather than an open-market purchase, it should be viewed as routine compensation unless accompanied by other insider trades reported separately.